Immunotherapy with NK cells

Immunotherapy with NK cells - Immunotherapy with NK cells

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002134

Enrollment

Registered

2009-07-08

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical study to investigate safety and efficacy on NK cells to health and cancer

Interventions

To investigate safety and efficacy on NK cells for human

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.5 years or more 2.performance status is 0-1 3.No serious abnormality in bone marrow, liver and/or renal functions

Exclusion criteria

Exclusion criteria: 1.Uncontrollable infection 2.Serious cardiac disease 3.Active autoimmune disease 4.Pulmonary fibrosis or interstitial pneumonia, or their history, or predisposition to them 5.Serious drug allergy

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Antitumor effect Progression-free survival Overall survival QOL Immunological responses	—

Countries

Japan,Asia(except Japan)

Contacts

Public Contactzhang benning

Harbin Medical University Department of Immunology

zbn-tky@umin.ac.jp86-13030028668

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026